Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. From licensing our platforms, to working with us as a trusted discovery service partner, we have collaborated with over 170+ partners and counting including 18 of Fortune 50 Biopharmaceutical companies to enable the discovery of their next breakthrough biologic medicines. With Alloy, you can: • Access our ever-growing stable of antibody and bispecific discovery platforms that blend in vivo and in vitro wet-lab capabilities with AI/ML. Discover with us through our services or by licensing our technologies for use in your lab. • Unlock intracellular targets with the therapeutic potential of T cell receptor (TCR) modalities through our fully integrated Keyway™ TCRm discovery service offering. • Reach genetic disease targets at the nucleic acid level with our novel AntiClastic™ ASO Format, which enhances the molecule's potency while minimizing off-target interaction and inflammatory response. • Co-build new biotechnology companies that leverage our core platforms and service capabilities with Alloy's affiliated Venture Studio, 82VS. Founded in 2017 and privately funded by visionary investors, Alloy is headquartered in Boston, MA, with labs in Cambridge, U.K.; Basel, CH; and Athens, GA. We reinvest 100% of our revenue back into innovation and access to innovation. Reach out, follow, and visit our website, to learn more about how we can make better medicines, together. https://www.alloytx.com/